根治性前列腺切除术后首次超敏前列腺特异性抗原预测高危前列腺癌病理患者的生存
研究纳入1991至2015年间269例根治性前列腺切除术后具有前列腺外侵犯和/或切缘阳性且未接受即刻辅助治疗的患者,术后3个月检测首次超敏前列腺特异性抗原(uPSA)。首次术后uPSA≥0.03ng/ml是生化复发、无骨转移生存、前列腺癌特异性生存和总生存的独立预测因子。作者认为对于首次术后uPSA≥0.03ng/ml的高危患者,单纯挽救性放疗可能不足。
要点
- 术后3个月首次uPSA≥0.03ng/ml是生化复发的独立预测因子(HR 9.4)。
- 首次uPSA≥0.03ng/ml是无骨转移生存的唯一预测因子(HR 9.7)。
- 作者认为首次uPSA≥0.03ng/ml的高危患者可考虑早期挽救性放疗,可能联合激素治疗。
核心结论
- 首次术后uPSA≥0.03ng/ml独立预测生化复发、无骨转移生存、前列腺癌特异性生存和总生存,优于传统危险因素。
- 对于首次术后uPSA≥0.03ng/ml的高危患者,单纯挽救性放疗可能不足。
研究设计与样本
- 研究纳入1991至2015年间269例根治性前列腺切除术后具有前列腺外侵犯和/或切缘阳性且未接受即刻辅助治疗的患者。
- 术后3个月检测首次uPSA,中位随访77个月。
主要发现
- 首次术后uPSA≥0.03ng/ml组 vs <0.03ng/ml组的5年生化复发率为86%(95%CI 71-93%)vs 39%(95%CI 25-51%),p<0.00001。
- 首次术后uPSA≥0.03ng/ml组 vs <0.03ng/ml组的10年无骨转移生存率为75%(95%CI 62-92%)vs 95%(95%CI 88-100%),p=0.0001。
- 首次术后uPSA≥0.03ng/ml组 vs <0.03ng/ml组的10年前列腺癌特异性生存率为84%(95%CI 73-96%)vs 100%(95%CI 100-100%),p=0.005。
- 首次术后uPSA≥0.03ng/ml组 vs <0.03ng/ml组的10年总生存率为81%(95%CI 70-93%)vs 98%(95%CI 94-100%),p=0.009。
- 多因素分析中,首次术后uPSA≥0.03ng/ml是生化复发的独立预测因子(HR 9.4,95%CI 5.8-15.4;p<0.00001),也是无骨转移生存(HR 9.7,95%CI 2.1-44.6;p=0.0034)、前列腺癌特异性生存(HR 13.5,95%CI 1.7-107.9;p=0.014)和总生存(HR 5.0,95%CI 1.4-18.3;p=0.014)的唯一预测因子。
关键数值与推荐
- 敏感性分析确定首次术后uPSA≥0.03ng/ml为预测生化复发的最佳阈值。
- 挽救性放疗后,首次术后uPSA≥0.03ng/ml独立预测更差的无骨转移生存(HR 5.9,95%CI 1.3-26.9;p=0.021)、前列腺癌特异性生存(HR 6.9,95%CI 0.9-55.8;p=0.07)和总生存(HR 4.5,95%CI 1.0-20.1;p=0.057)。
临床怎么用
- 作者认为首次术后uPSA≥0.03ng/ml的高危患者可考虑早期挽救性放疗,可能联合激素治疗。
局限性
- 局限性包括回顾性设计和潜在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ultrasensitive prostate-specific antigen (uPSA) has untapped potential for optimizing management following radical prostatectomy (RP) in terms of facilitating early salvage, minimizing overtreatment, and identifying those at risk of occult systemic disease. OBJECTIVE: To test first postoperative uPSA for prediction of outcome in patients with adverse pathology after RP. DESIGN, SETTING, AND PARTICIPANTS: Patients with extraprostatic extension and/or a positive margin who did not receive immediate adjuvant therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: First uPSA was measured at 3 mo after RP. The study endpoints were biochemical relapse (BCR), defined as PSA ≥0.2ng/ml, bone metastasis-free survival (BMFS), prostate cancer-specific survival (PCSS), overall survival (OS), and salvage radiation therapy (SRT) success. Outcome results were compared using the Kaplan-Meier method and multivariate analysis (MVA). RESULTS AND LIMITATIONS: The cohort consisted of 269 RP patients from 1991-2015 with median follow-up of 77 mo. Sensitivity analysis identified first postoperative uPSA of ≥0.03ng/ml as the optimal threshold for predicting BCR. First postoperative uPSA ≥0.03 versus <0.03ng/ml was associated with worse 5-yr BCR (86%, 95% confidence interval [CI] 71-93% vs 39%, 95% CI 25-51%; p<0.00001), 10-yr BMFS (75%, 95% CI 62-92% vs 95%, 95% CI 88-100%; p=0.0001), 10-yr PCSS (84%, 95% CI 73-96% vs 100%, 95% CI 100-100%; p=0.005), and 10-yr OS (81%, 95% CI 70-93% vs 98%, 95% CI 94-100%; p=0.009). On MVA, first postoperative uPSA ≥0.03ng/ml was an independent predictor of BCR (hazard ratio [HR] 9.4, 95% CI 5.8-15.4; p<0.00001) and the only predictor for BMFS (HR 9.7, 95% CI 2.1-44.6; p=0.0034), PCSS (HR 13.5, 95% CI 1.7-107.9; p=0.014), and OS (HR 5.0, 95% CI 1.4-18.3; p=0.014). Following SRT, first postoperative uPSA ≥0.03ng/ml independently predicted worse BMFS (HR 5.9, 95% CI 1.3-26.9; p=0.021), PCSS (HR 6.9, 95% CI 0.9-55.8; p=0.07), and OS (4.5, 95% CI 1.0-20.1; p=0.057). Limitations include the retrospective design and potential selection bias. CONCLUSIONS: First postoperative uPSA ≥0.03ng/ml independently predicts BCR, BMFS, PCSS, and OS better than traditional risk factors. SRT alone may be insufficient for patients with high-risk disease when first postoperative uPSA is ≥0.03ng/ml. PATIENT SUMMARY: When the first postprostatectomy ultrasensitive prostate-specific antigen level is ≥0.03ng/ml, patients are at higher risk of recurrent and occult prostate cancer. They should be considered for early salvage radiotherapy, possibly with hormone therapy.
引用
- Kang JJ, Reiter RE, Steinberg ML, et al. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. Eur Urol Oncol. 2018. PMID: 31158076. doi:10.1016/j.euo.2018.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。